EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction

Hanieh Karimi, Thomas H Shaffer, Erik Stauff, Vinay V R Kandula, Heidi H Kecskemethy, Lauren W Averill, Xuyi Yue iD

International Journal of Molecular Sciences · 28.02.2026 · 27 (5) · 2290

DOI: 10.3390/ijms27052290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2026. Verfasst von Hanieh Karimi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Nemours Children's Health, Wilmington, DE 19803, USA. Hauptthemen laut MEDLINE: Alpha Particles, Beta Particles, Nuclear Medicine, Radiopharmaceuticals. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Nemours Foundation, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceutical therapy (RPT) has emerged as a transformative modality in oncology, particularly for patients with metastatic or inoperable tumors. By leveraging molecularly targeted carriers conjugated to cytotoxic radionuclides, RPT enables precise delivery of ionizing radiation to tumor sites while minimizing off-target effects. Central to this approach are alpha (α) and beta (β) particle-emitting radionuclides. This review aims to provide a comprehensive overview of all clinically relevant alpha and beta emitters and incorporates the most recent advances from 2017–2025, offering a comprehensive and up-to-date perspective. Alpha and beta emitters hold significant promises for the future, especially in nuclear medicine, energy, and environmental monitoring. Medically, these emitters are at the forefront of targeted radiotherapy, offering new hope for cancer treatment. Alpha emitters such as Actinium-225 and Radium-223 are gaining attention for their high linear energy transfer, which allows them to effectively kill cancer cells while minimizing damage to surrounding healthy tissues. Beta emitters, including Lutetium-177 and Iodine-131, are already widely used for treating thyroid cancer, neuroendocrine tumors, and prostate cancer. They offer a longer range in tissue penetration than alpha particles, making them suitable for larger or more diffuse tumors. Alpha and beta emitters hold tremendous promise in targeted radiotherapy. However, current research is limited by an incomplete understanding of resistance pathways, insufficient long-term safety and efficacy data, and underdeveloped personalized treatment frameworks. As production technologies improve and safety protocols advance, these emitters will likely play an even more prominent role in both health care and scientific innovation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha ParticlesBeta ParticlesNuclear MedicineRadiopharmaceuticalsNeoplasmsRadioisotopesTranslational Research, BiomedicalHumansAnimals

Stichwörter der Autor:innen

alpha emittersbeta emittersclinical investigationlinear energy transfer (LET)molecular targetingradiopharmaceutical therapy (RPT)radiotheranostics

Substanzen

RadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Department of Radiology, Nemours Children's Health, Wilmington, DE 19803, USA.
  • Diagnostic & Research PET/MR Center, Nemours Children's Health, Wilmington, DE 19803, USA.
  • Nemours Biomedical Research, Nemours Children's Health, Wilmington, DE 19803, USA.
  • Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Department of Psychological and Brain Sciences, University of Delaware, Newark, DE 19716, USA.

ORCID-Profile: Xuyi Yue

Förderung

  • NIGMS NIH HHS
  • Nemours Foundation
  • NIBIB NIH HHS
  • National Institute of General Medical Sciences of the National Institutes of Health
  • State of Delaware
  • National Institute of Biomedical Imaging and Bioengineering

Zitieren

APA

Karimi, H., Shaffer, T. H., Stauff, E., Kandula, V. V. R., Kecskemethy, H. H., Averill, L. W., & Yue, X. (2026). Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction. International Journal of Molecular Sciences, 27(5), 2290. https://doi.org/10.3390/ijms27052290

Vancouver

Karimi H, Shaffer TH, Stauff E, Kandula VVR, Kecskemethy HH, Averill LW, et al. Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction. International Journal of Molecular Sciences. 2026;27(5):2290. doi:10.3390/ijms27052290

BibTeX
@article{Karimi2026,
  author = {Karimi, Hanieh and Shaffer, Thomas H and Stauff, Erik and Kandula, Vinay V R and Kecskemethy, Heidi H and Averill, Lauren W and Yue, Xuyi},
  title = {Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {2290},
  doi = {10.3390/ijms27052290}
}
Kostenlos starten →